S&P 500   4,210.24 (+2.13%)
DOW   32,774.41 (+0.00%)
QQQ   325.93 (+2.79%)
AAPL   169.24 (+2.62%)
MSFT   289.16 (+2.43%)
META   178.34 (+5.82%)
GOOGL   119.70 (+2.63%)
AMZN   142.69 (+3.53%)
TSLA   883.07 (+3.89%)
NVDA   180.97 (+5.92%)
NIO   20.05 (+4.59%)
BABA   92.43 (+1.36%)
AMD   99.05 (+3.67%)
MU   61.40 (+3.80%)
T   18.01 (-0.50%)
CGC   3.29 (+14.63%)
GE   77.14 (+2.95%)
F   15.50 (+2.04%)
DIS   112.43 (+3.98%)
AMC   23.67 (+5.43%)
PYPL   98.91 (+4.69%)
PFE   49.95 (+0.34%)
NFLX   244.11 (+6.16%)
S&P 500   4,210.24 (+2.13%)
DOW   32,774.41 (+0.00%)
QQQ   325.93 (+2.79%)
AAPL   169.24 (+2.62%)
MSFT   289.16 (+2.43%)
META   178.34 (+5.82%)
GOOGL   119.70 (+2.63%)
AMZN   142.69 (+3.53%)
TSLA   883.07 (+3.89%)
NVDA   180.97 (+5.92%)
NIO   20.05 (+4.59%)
BABA   92.43 (+1.36%)
AMD   99.05 (+3.67%)
MU   61.40 (+3.80%)
T   18.01 (-0.50%)
CGC   3.29 (+14.63%)
GE   77.14 (+2.95%)
F   15.50 (+2.04%)
DIS   112.43 (+3.98%)
AMC   23.67 (+5.43%)
PYPL   98.91 (+4.69%)
PFE   49.95 (+0.34%)
NFLX   244.11 (+6.16%)
S&P 500   4,210.24 (+2.13%)
DOW   32,774.41 (+0.00%)
QQQ   325.93 (+2.79%)
AAPL   169.24 (+2.62%)
MSFT   289.16 (+2.43%)
META   178.34 (+5.82%)
GOOGL   119.70 (+2.63%)
AMZN   142.69 (+3.53%)
TSLA   883.07 (+3.89%)
NVDA   180.97 (+5.92%)
NIO   20.05 (+4.59%)
BABA   92.43 (+1.36%)
AMD   99.05 (+3.67%)
MU   61.40 (+3.80%)
T   18.01 (-0.50%)
CGC   3.29 (+14.63%)
GE   77.14 (+2.95%)
F   15.50 (+2.04%)
DIS   112.43 (+3.98%)
AMC   23.67 (+5.43%)
PYPL   98.91 (+4.69%)
PFE   49.95 (+0.34%)
NFLX   244.11 (+6.16%)
S&P 500   4,210.24 (+2.13%)
DOW   32,774.41 (+0.00%)
QQQ   325.93 (+2.79%)
AAPL   169.24 (+2.62%)
MSFT   289.16 (+2.43%)
META   178.34 (+5.82%)
GOOGL   119.70 (+2.63%)
AMZN   142.69 (+3.53%)
TSLA   883.07 (+3.89%)
NVDA   180.97 (+5.92%)
NIO   20.05 (+4.59%)
BABA   92.43 (+1.36%)
AMD   99.05 (+3.67%)
MU   61.40 (+3.80%)
T   18.01 (-0.50%)
CGC   3.29 (+14.63%)
GE   77.14 (+2.95%)
F   15.50 (+2.04%)
DIS   112.43 (+3.98%)
AMC   23.67 (+5.43%)
PYPL   98.91 (+4.69%)
PFE   49.95 (+0.34%)
NFLX   244.11 (+6.16%)
NASDAQ:KNSA

Kiniksa Pharmaceuticals - KNSA Stock Forecast, Price & News

$12.92
+0.09 (+0.70%)
(As of 08/10/2022 04:15 PM ET)
Add
Compare
Today's Range
$12.64
$13.22
50-Day Range
$7.60
$13.41
52-Week Range
$7.36
$15.24
Volume
323,405 shs
Average Volume
335,264 shs
Market Capitalization
$895.05 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$34.00

Kiniksa Pharmaceuticals MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
163.2% Upside
$34.00 Price Target
Short Interest
Healthy
2.79% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.75mentions of Kiniksa Pharmaceuticals in the last 14 days
Based on 16 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($1.46) to ($1.13) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.38 out of 5 stars

Medical Sector

405th out of 1,108 stocks

Pharmaceutical Preparations Industry

186th out of 542 stocks

KNSA stock logo

About Kiniksa Pharmaceuticals (NASDAQ:KNSA) Stock

Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, which is in Phase 2a clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response. Kiniksa Pharmaceuticals, Ltd. was incorporated in 2015 and is based in Hamilton, Bermuda.

Kiniksa Pharmaceuticals Stock Performance

Shares of NASDAQ:KNSA opened at $12.83 on Wednesday. Kiniksa Pharmaceuticals has a 52-week low of $7.36 and a 52-week high of $15.24. The company has a market capitalization of $888.81 million, a PE ratio of -7.92 and a beta of -0.12. The company has a fifty day moving average of $10.16 and a 200-day moving average of $10.06.

Receive KNSA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Kiniksa Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

KNSA Stock News Headlines

Kiniksa Pharmaceuticals: Q4 Earnings Insights
See More Headlines
Receive KNSA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Kiniksa Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

KNSA Company Calendar

Last Earnings
11/01/2021
Today
8/10/2022
Next Earnings (Estimated)
11/07/2022
Fiscal Year End
12/31/2022

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:KNSA
Fax
N/A
Employees
215
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$34.00
High Stock Price Forecast
$34.00
Low Stock Price Forecast
$34.00
Forecasted Upside/Downside
+163.2%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
2 Analysts

Profitability

Net Income
$-157,920,000.00
Net Margins
-124.52%
Pretax Margin
-121.40%

Debt

Sales & Book Value

Annual Sales
$38.54 million
Book Value
$2.65 per share

Miscellaneous

Free Float
31,472,000
Market Cap
$895.05 million
Optionable
Not Optionable
Beta
-0.12

Key Executives

  • Mr. Sanj K. Patel (Age 52)
    CEO & Chairman
    Comp: $1.61M
  • Dr. John F. Paolini (Age 57)
    Sr. VP & Chief Medical Officer
    Comp: $710.86k
  • Mr. Mark Ragosa C.F.A. (Age 47)
    Sr. VP & CFO
  • Mr. Eben Tessari (Age 40)
    Sr. VP & COO
  • Mr. Michael R. Megna CPA (Age 51)
    Chief Accounting Officer & Group VP of Fin.
  • Ms. Mei Jang
    Sr. VP of Technical Operations
  • Rachel Frank
    Associate Director of Investor Relations
  • Mr. Chad Morin
    Sr. VP, Chief Compliance Officer & Data Protection Officer
  • Ms. Madelyn Zeylikman
    SVP, Gen. Counsel & Sec.
  • Ms. Melissa Manno
    SVP & Chief HR Officer













KNSA Stock - Frequently Asked Questions

Should I buy or sell Kiniksa Pharmaceuticals stock right now?

2 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Kiniksa Pharmaceuticals in the last year. There are currently 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" KNSA shares.
View KNSA analyst ratings
or view top-rated stocks.

What is Kiniksa Pharmaceuticals' stock price forecast for 2022?

2 brokerages have issued 12 month price targets for Kiniksa Pharmaceuticals' shares. Their KNSA share price forecasts range from $34.00 to $34.00. On average, they predict the company's stock price to reach $34.00 in the next twelve months. This suggests a possible upside of 160.7% from the stock's current price.
View analysts price targets for KNSA
or view top-rated stocks among Wall Street analysts.

How have KNSA shares performed in 2022?

Kiniksa Pharmaceuticals' stock was trading at $11.77 on January 1st, 2022. Since then, KNSA shares have increased by 10.8% and is now trading at $13.04.
View the best growth stocks for 2022 here
.

When is Kiniksa Pharmaceuticals' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, November 7th 2022.
View our KNSA earnings forecast
.

How were Kiniksa Pharmaceuticals' earnings last quarter?

Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) announced its quarterly earnings data on Monday, November, 1st. The company reported ($0.44) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.65) by $0.21. The firm earned $12.10 million during the quarter, compared to the consensus estimate of $9.92 million. Kiniksa Pharmaceuticals had a negative net margin of 124.52% and a negative trailing twelve-month return on equity of 62.36%.

What is Sanj K. Patel's approval rating as Kiniksa Pharmaceuticals' CEO?

1 employees have rated Kiniksa Pharmaceuticals Chief Executive Officer Sanj K. Patel on Glassdoor.com. Sanj K. Patel has an approval rating of 100% among the company's employees. This puts Sanj K. Patel in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Kiniksa Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Kiniksa Pharmaceuticals investors own include Exelixis (EXEL), CRISPR Therapeutics (CRSP), Pfizer (PFE), VBI Vaccines (VBIV), SCYNEXIS (SCYX), Sorrento Therapeutics (SRNE), AbbVie (ABBV), Dicerna Pharmaceuticals (DRNA), Vaxart (VXRT) and Advanced Micro Devices (AMD).

When did Kiniksa Pharmaceuticals IPO?

(KNSA) raised $126 million in an IPO on Thursday, May 24th 2018. The company issued 7,000,000 shares at $17.00-$19.00 per share. Goldman Sachs and J.P. Morgan served as the underwriters for the IPO and JMP Securities and Wedbush PacGrow were co-managers.

What is Kiniksa Pharmaceuticals' stock symbol?

Kiniksa Pharmaceuticals trades on the NASDAQ under the ticker symbol "KNSA."

Who are Kiniksa Pharmaceuticals' major shareholders?

Kiniksa Pharmaceuticals' stock is owned by many different institutional and retail investors. Top institutional investors include Rice Hall James & Associates LLC (1.18%), Walleye Capital LLC (0.43%), Integral Health Asset Management LLC (0.34%), Swiss National Bank (0.10%), Hennion & Walsh Asset Management Inc. (0.10%) and Personal CFO Solutions LLC (0.02%). Insiders that own company stock include John F Paolini, Sanj K Patel and Thomas W Beetham.
View institutional ownership trends
.

How do I buy shares of Kiniksa Pharmaceuticals?

Shares of KNSA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Kiniksa Pharmaceuticals' stock price today?

One share of KNSA stock can currently be purchased for approximately $13.04.

How much money does Kiniksa Pharmaceuticals make?

Kiniksa Pharmaceuticals (NASDAQ:KNSA) has a market capitalization of $903.36 million and generates $38.54 million in revenue each year. The company earns $-157,920,000.00 in net income (profit) each year or ($1.62) on an earnings per share basis.

How many employees does Kiniksa Pharmaceuticals have?

The company employs 215 workers across the globe.

How can I contact Kiniksa Pharmaceuticals?

Kiniksa Pharmaceuticals' mailing address is CLARENDON HOUSE 2 CHURCH STREET, HAMILTON D0, HM11. The official website for the company is www.kiniksa.com. The company can be reached via phone at 448081896257 or via email at ir@kiniksa.com.

This page (NASDAQ:KNSA) was last updated on 8/10/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.